secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001641172-25-012603
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA updates on Ketamir-2 Phase 1 progress, plans Phase IIa in neuropathic pain by end of 2025
--------------------------------------------------------------------------------

- Participating in BIO International Convention June 16-19, 2025 for partnering and licensing discussions.
- Second dosing cohort of Ketamir-2 Phase 1 completed; company preparing to initiate third cohort.
- Phase IIa trial in neuropathic pain expected to start by end of 2025.
- Preclinical studies ongoing for PTSD and topical formulation for localized inflammatory pain.
- Finalizing regulatory filings for SKNY acquisition; SKNY-1 targets smoking cessation and obesity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/0001641172-25-012603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-012603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer